Cryoport, Inc. (CYRX) stock
CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/3025% above fair value
$19.89−0.21 (-1.04%)
Close on Nov 13, 2026Market cap $1.01BP/E –Yield –
Cryoport EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cryoport's EPS for the twelve months ending Sep 30, 2026 was -$0.97, down 177.6% year over year. For fiscal 2025 it was $1.40. The highest annual figure on record is $1.40 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40 | – |
| FY2024 | Dec 31, 2024 | -$2.49 | – |
| FY2023 | Dec 31, 2023 | -$2.21 | – |
| FY2022 | Dec 31, 2022 | -$0.93 | – |
| FY2021 | Dec 31, 2021 | -$6.18 | – |
| FY2020 | Dec 31, 2020 | -$1.94 | – |
| FY2019 | Dec 31, 2019 | -$0.55 | – |
| FY2018 | Dec 31, 2018 | -$0.34 | – |
| FY2016 | Mar 31, 2016 | -$2.05 | – |
| FY2015 | Mar 31, 2015 | -$2.44 | – |
| FY2014 | Mar 31, 2014 | -$4.81 | – |
| FY2013 | Mar 31, 2013 | -$2.04 | – |
| FY2012 | Mar 31, 2012 | -$3.24 | – |
| FY2011 | Mar 31, 2011 | -$5.52 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | -$0.25 | – |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$0.20 | -109.4% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$0.25 | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$0.27 | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$0.18 | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $2.13 | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$0.28 | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$0.42 | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$0.02 | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$1.62 | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$0.43 | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$1.31 | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$0.31 | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$0.42 | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$0.16 | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$0.24 | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$0.15 | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$0.23 | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$0.31 | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$5.46 | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$0.18 | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$0.16 | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$0.13 | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$1.32 | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$0.29 | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$0.15 | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$0.11 | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$0.03 | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$0.35 | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$0.08 | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$0.08 | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$0.08 | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$0.07 | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$0.09 | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$0.10 | – |
| Q4 FY2016CQ1 2016 | Mar 31, 2016 | $0.00 | – |
| Q3 FY2016CQ4 2015 | Dec 31, 2015 | -$0.42 | – |
| Q2 FY2016CQ3 2015 | Sep 30, 2015 | -$0.41 | – |
| Q1 FY2016CQ2 2015 | Jun 30, 2015 | -$1.31 | – |
| Q4 FY2015CQ1 2015 | Mar 31, 2015 | -$0.26 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?